Shares of Astera Labs, Inc. (NASDAQ:ALAB - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty-one analysts that are covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a hold recommendation, twelve have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $348.33.
A number of analysts recently commented on the company. Barclays boosted their target price on Astera Labs from $200.00 to $325.00 and gave the company an "equal weight" rating in a research report on Monday, July 20th. Weiss Ratings reissued a "hold (c)" rating on shares of Astera Labs in a research note on Tuesday, August 18th. Stifel Nicolaus upped their target price on Astera Labs from $260.00 to $460.00 and gave the stock a "buy" rating in a research report on Wednesday, June 24th. Zacks Research upgraded Astera Labs from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 11th. Finally, Needham & Company LLC boosted their price target on shares of Astera Labs from $260.00 to $425.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th.
Get Our Latest Stock Report on Astera Labs
Insider Transactions at Astera Labs
In related news, General Counsel Philip Mazzara sold 6,801 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $340.50, for a total value of $2,315,740.50. Following the sale, the general counsel owned 96,542 shares in the company, valued at $32,872,551. This represents a 6.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Manuel Alba sold 183,000 shares of the company's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $280.13, for a total transaction of $51,263,790.00. Following the completion of the sale, the director owned 253,863 shares in the company, valued at $71,114,642.19. This represents a 41.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 396,059 shares of company stock valued at $122,605,660. Corporate insiders own 10.40% of the company's stock.
Institutional Trading of Astera Labs
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALAB. BlackRock Inc. bought a new position in shares of Astera Labs in the second quarter valued at approximately $6,609,581,000. Atreides Management LP boosted its position in shares of Astera Labs by 108.9% during the first quarter. Atreides Management LP now owns 3,365,787 shares of the company's stock valued at $368,890,000 after buying an additional 1,754,593 shares during the last quarter. Van ECK Associates Corp grew its holdings in Astera Labs by 20.0% during the second quarter. Van ECK Associates Corp now owns 2,237,961 shares of the company's stock worth $1,080,980,000 after buying an additional 373,545 shares in the last quarter. Bank of America Corp DE bought a new stake in Astera Labs during the second quarter worth $1,061,791,000. Finally, Fred Alger Management LLC raised its position in Astera Labs by 25.5% in the 4th quarter. Fred Alger Management LLC now owns 1,934,688 shares of the company's stock valued at $321,855,000 after buying an additional 393,250 shares during the last quarter. 60.47% of the stock is owned by institutional investors.
Astera Labs Trading Up 0.1%
NASDAQ:ALAB opened at $356.42 on Friday. Astera Labs has a 12 month low of $97.89 and a 12 month high of $499.48. The stock has a market capitalization of $61.84 billion, a price-to-earnings ratio of 176.45 and a beta of 3.67. The firm has a fifty day simple moving average of $307.86 and a two-hundred day simple moving average of $281.52.
Astera Labs (NASDAQ:ALAB - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.11. The firm had revenue of $392.40 million for the quarter, compared to analyst estimates of $360.85 million. Astera Labs had a net margin of 30.74% and a return on equity of 19.24%. The business's quarterly revenue was up 104.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.44 earnings per share. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. Equities analysts predict that Astera Labs will post 2.7 earnings per share for the current fiscal year.
About Astera Labs
(
Get Free Report)
Astera Labs, Inc is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help data centers connect and manage processors, memory, storage, and networking components in high-performance computing systems.
The company's portfolio includes Aries PCI Express and Compute Express Link (CXL) smart memory controllers, Scorpio PCIe switches, Taurus Ethernet fabric switches, and Leo CXL memory connectivity products.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astera Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astera Labs wasn't on the list.
While Astera Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.